SECURITY Did Not Establish Noninferiority  by Perneger, Thomas
J A C C V O L . 6 5 , N O . 2 1 , 2 0 1 5 Letters
J U N E 2 , 2 0 1 5 : 2 3 5 2 – 6 1
23594. Ibanez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol
on infarct size in ST-segment-elevation myocardial infarction patients
undergoing primary percutaneous coronary intervention: the Effect of
Metoprolol in Cardioprotection During an Acute Myocardial Infarction
(METOCARD-CNIC) trial. Circulation 2013;128:1495–503.
5. Pizarro G, Fernández-Friera L, Fuster V, et al. Long-term beneﬁt of early
pre-reperfusion metoprolol administration in patients with acute myocardial
infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in
Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol
2014;63:2356–62.Noninferiority of
6 Versus 12 Months of
Dual Antiplatelet TherapyWith great interest, I read the article by Colombo et al.
(1) that examined the noninferiority of 6 versus 12
months of dual antiplatelet therapy (DAPT) in
patients undergoing percutaneous coronary inter-
vention with second-generation drug-eluting stents.
The investigators described in the Results section
(p. 2091) that “There was at least 1 occurrence of the
primary composite endpoint by 12 months in 31 pa-
tients in the 6-month DAPT group (4.5%; 95% CI: 2.9
to 6.1) and 27 patients in the 12-month DAPT group
(3.7%; 95% CI: 2.3 to 5.1; p ¼ 0.469) (Table 5). There
was a 0.8% (95% CI: -2.4 to 1.7) difference in occur-
rence of the primary endpoint between the 6-month
and 12-month groups. The upper limit of the 95% CI
was lower than the pre-set margin of 2%, conﬁrming
the noninferiority hypothesis (p < 0.05).” However,
on the basis of the result (31 of 682 vs. 27 of 717) in
Table 5, the 95% conﬁdence interval (CI) for the dif-
ference between 2 sample proportions is -1.3% to
2.9% (90% CI: -1.0 to 2.5). Therefore, the upper limit
of the 95% CI appears more than the pre-set margin of
2%, rejecting the noninferiority hypothesis of 6
months versus 12 months of DAPT. It would be of
great help if the investigators could provide the
method they used to calculate 95% CI.*Hideaki Kaneda, MD, PhD
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Establish NoninferiorityIn presenting the results of the SECURITY (Second-
Generation Drug-Eluting Stent Implantation Fol-
lowed by 6- Versus 12-Month Dual Antiplatelet
Therapy) trial, Colombo et al. (1) concluded that
“6 months of DAPT appeared noninferior to a
12-month regimen with respect to the primary com-
posite endpoint.” However, this conclusion, repeated
several times in the paper, is not supported by the
data.
The composite event was observed in 31 of 682
patients in the 6-month treatment arm, and in 27 of
717 patients in the 12-month arm. The risks were
correctly reported as 4.5% versus 3.7%, and the risk
difference as 0.8%. The 95% conﬁdence interval was
given as -2.4% to 1.7%, such that “the upper limit of
the 95% CI was lower than the pre-set margin of 2%,
conﬁrming the noninferiority hypothesis.” Unfortu-
nately, the conﬁdence bounds are incorrect. The
tell-tale sign of a problem is the asymmetry; the
conﬁdence interval should be approximately sym-
metric about the point estimate of 0.8%. Reanalysis
shows an asymptotic 95% conﬁdence interval of -1.3%
to 2.9%, which exceeds the noninferiority margin. If
an exact conﬁdence interval is preferred, which may
be a good idea given the low numbers of events, the
bounds are -1.7% to 3.9%. This means that the data
are compatible with an absolute excess risk of a
composite event of up to 2.9% (or 3.9%) in a patient
treated for 6 months, compared with a patient treated
for 12 months. Noninferiority up to an excess risk of
2% does not hold.
The problem remains if a 1-sided 95% conﬁdence
interval is obtained, as it should according to the
Methods section. A 1-sided upper limit on the risk
difference of 0.8% is 2.5% (asymptotic method) or
3.4% (exact method). In all instances, the upper limit
exceeds the noninferiority margin.
Another issue that argues against noninferiority is
the rather high proportion of patients (34%) in
the 6-month treatment group who continued their
medications beyond the scheduled stopping time.
Non-compliance with the assigned treatment dilutes
the contrast between the groups. This favors the null
hypothesis and causes a conservative bias in su-
periority trials: indeed, if a signiﬁcant difference is
observed between the treatment arms despite
noncompliance, the true difference must be even
greater. In contrast, in a noninferiority trial, the bias
caused by noncompliance runs against the tested
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2360hypothesis of inferiority (that one hopes to reject to
establish noninferiority). In the case of the SECU-
RITY trial, if all patients in the 6-month arm had
stopped treatment at the planned time, more com-
posite events may have occurred and the difference
with the 12-month treatment arm may have been
greater.
In any case, it is unfortunate that the conclusions
of this trial should contradict the results because of
what appears to be an arithmetic error.*Thomas Perneger, MD, PhD
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SECURITY Did Not Establish NoninferiorityWe thank Dr. Kaneda and Dr. Perneger for their
interest in our paper (1), giving us the possibility to
clarify some relevant aspects of the statistical anal-
ysis of our SECURITY (Second-Generation Drug-
Eluting Stent Implantation Followed by 6- Versus
12-Month Dual Antiplatelet Therapy) randomized
noninferiority trial.
We submitted both letters to Professor Bruno
Mario Cesana, the statistician of the SECURITY trial,
and his answer is the following:
Because the conﬁdence interval (CI) calculation
proposed methods (2,3) for the difference be-
tween 2 proportions give different results
possibly leading to different conclusions in the
analysis of noninferiority studies in which the
CI approach is used, we calculated, according
to Thomas and Gart (4), the CI limits of the
odds ratio (OR) that can be “translated” into
the upper and the lower CI limits for the dif-
ference between 2 proportions. We used the
approximate OR 90% CI, due to the much
higher coverage of the “exact” OR CI.As a result, the data in Table 5 give an OR of
1.21 with 90% CI: 0.78 to 1.89, translated as
-0.0093 to 0.024. Consequently, “6 to 12
months” should be considered “6 months” and
“95% CI” as “90% CI” only for the primary
efﬁcacy composite endpoint. In addition, the
90% CI are 0.49% to 1.29% for the comparison
at 6 months and -0.93% to 2.4% for the com-
parison at 12 months.
The unilateral 95% upper limit of 2.4%,
greater than 2%, does not allow us to conclude
for the noninferiority. However, from the re-
sults of the landmark analysis (not shown in
the paper because of space limitations) after
having excluded the events that occurred in
the ﬁrst 6 months in which the treatment is
equal for the 2 arms and in which, by chance,
more events occurred in the 6-month dual
antiplatelet therapy (DAPT) arm, there are
23 events on 674 patients (0.0341; 95%
CI: 0.0234 to 0.0480) in the 6-month DAPT
arm against 22 events on 712 patients (0.0341;
95% CI: 0.0210 to 0.0438) in the 12-month
DAPT arm.
The SECURITY trial (1) has been stopped
without enrolling the planned sample size of
1,370 patients in each treatment group; so, if
the proportions are considered on the expected
sample size, the 95% unilateral upper limit of
their difference is 0.020 and 0.019 from Agresti
and Caffo’s (3) method.
As we have been cautious in the SECURITY paper
(1) to state the conclusiveness of noninferiority, the
same applies to the lack of noninferiority. The bot-
tom line is that with insufﬁcient power, the con-
clusions remain uncertain. Nevertheless, the data
obtained from the SECURITY study are a contribu-
tion to test the hypothesis that shorter duration of
DAPT following implantation of second-generation
drug-eluting stents is as safe and effective as 12
months of therapy. This study underscores that
larger patient enrollment is necessary to answer this
question.*Antonio Colombo, MD
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